TABLE 4.
Susceptibility to RT inhibitors of strains with Q151M or T69S-SS
| Recombinant virus straina | Resistance pattern | 50% Inhibitory concn (μM)b
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZDV | ddI | ddC | d4T | 3TC | ABC | PMEA | PMPA | DLV | NVP | EFZ | ||
| IT1-31.8R | Q151M | 0.075 (19×) | 94 (5×) | 7.1 (2×) | 1.03 (5×) | 4.8 (1×) | 4.65 (1×) | 1.85 (0.3×) | 1.22 (0.3×) | 0.041 (4×) | 0.150 (3×) | 0.0022 (3×) |
| IT2-31.15R | Q151M | 0.150 (37×) | 121.6 (6×) | 29 (8×) | 3.44 (16×) | 11 (2×) | 20.2 (3×) | 3.1 (0.5×) | 2.3 (0.6×) | 0.041 4×) | 0.038 (1×) | 0.0010 (1×) |
| SP1-9612024R | Q151M | 0.187 (47×) | 116.9 (6×) | 21 (6×) | 2.46 (11×) | 18 (4×) | 20.9 (3×) | 4.37 (0.7×) | 3.693 (1×) | 0.021 (2×) | 0.075 (1×) | 0.0010 (1×) |
| SW1-10671R | Q151M | 4.494 (1124×) | >211.8 (>11×) | 37 (10×) | 7.14 (33×) | >44 (>9×) | 48.6 (7×) | 13.9 (2.2×) | 22.82 (6×) | 0.185 (18×) | 0.713 (14×) | 0.0029 (4×) |
| SW2-11546R | Q151M | 2.884 (721×) | 116.10 (6×) | 33 (9×) | 7.14 (33×) | >44 (>9×) | 29.7 (4×) | 11.19 (1.7×) | 14.98 (4×) | 0.041 (4×) | 0.014 (1×) | 0.0006 (1×) |
| SW3-10125R | T69S-SS | >7.491 (>1873×) | 22.46 (1×) | 31 (9×) | 3.48 (16×) | >66 (>14×) | 22.7 (3×) | 8.04 (1.2×) | 23.17 (6×) | 0.014 (1×) | 0.047 (1×) | 0.0006 (1×) |
| HIV-1 IIIbR | Wild type | 0.004 | 19.32 | 3.6 | 0.22 | 4.6 | 7.24 | 6.47 | 3.76 | 0.010 | 0.053 | 0.0008 |
a
The patient designation is followed by the sample code. The suffix R discriminates the original virus strain from the recombinant virus strain.
b
The results are the averages of two experiments performed in triplicate. The values for wild-type reference strain HIV-1 IIIbR are averages of 6 to 10 independent tests performed in triplicate. The fold resistance compared to the resistance of HIV-1 IIIbR is indicated in parentheses. Abbreviations: ZDV, zidovudine; ddI, didanosine; ddC, zalcitabine; d4T, stavudine; 3TC, lamivudine; ABC, abacavir; PMEA, adefovir; PMPA, tenofovir, DLV, delavirdine; NVP, nevirapine; EFZ, efavirenz.